Expert Interview
A second look: Discussing the treatment landscape for cervical cancer
Ticker(s): MRK, PFEInstitution: Mount Sinai Medical Center
- Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center
- Member of the Board of Directors at the GOG Foundation and the Uterine Cancer Lead for GOG Partners.
- Professor of Obstetrics and Gynecology at Florida International University.
What are the different lines of treatment for cervical cancer, and how is Tivdak used in the treatment landscape?
Can you clarify the typical response rate and progression-free survival for second-line patients receiving Tivdak, and what was the control arm in the study?
How tolerable is Tivdak in terms of safety, particularly regarding eye toxicity, and is it being considered for earlier therapy in combination with pembrolizumab?
Added By: wilson_adminWhat potential do new therapies such as the Nectin-4 ADC and TROP-2 ADC show in cervical cancer treatment, and how do they compare to existing standards like Tivdak or bevacizumab?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
